Dose: 0.357 mg/kg
Single Dose: 0.36 (0.357)
Frequency: 8 hourly
Route: PO
Instructions: Initially for 1 Week

. It is of Synthetic origin and belongs to Piperidyl Benzanilide. It belongs to Na-Channel Antiarrhythmic antagonist pharmacological group on the basis of mechanism of action and also classified in Anti arrhythmic agents pharmacological group.The Molecular Weight of Encainide (HCl) is 389.00.

Encainide (HCl) is contraindicated in conditions like Cardiogenic shock,Cardiac failure,Conduction system disease.

The severe or irreversible adverse effects of Encainide (HCl), which give rise to further complications include Congestive heart failure, Sinoatrial block.Encainide (HCl) produces potentially life-threatening effects which include Arrhythmias. which are responsible for the discontinuation of Encainide (HCl) therapy.The signs and symptoms that are produced after the acute overdosage of Encainide (HCl) include Bradycardia, Hypotension, Cardiogenic shock, Asystole, Torsades de pointes, AV block.The symptomatic adverse reactions produced by Encainide (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Dyspnea, Insomnia, Tinnitus, Blurred vision, Metallic taste.

Encainide (HCl) is primarily indicated in conditions like Cardiac arrhythmia, Supraventricular arrhythmias, Ventricular arrhythmias.

Encainide (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCimetidine (HCl)Paroxetine These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Serum glucose level

Drug should not be given to Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Caps Store Below 40°C. Protect from Moisture and Heat.

It should be used with caution in patients with a history of a myocardial infarction with left ventriuclar dysfunction because of an increased risk of arrhythmias. Electrolyte imbalances, such as hyperkalemia or hypokalemia, should be corrected before beginning therapy with any antiarrhythmic agent. It should be used with caution in patients with diabetes mellitus or pre-existing glucose-intolerance. Blood glucose monitioring is recommended. Encainide should be used with caution in patients with kidney or liver impairment, because hepatic impairment may reduced elimination rate of encainide which may lead to toxicity.